

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**Form 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of July 2018  
Commission File Number 001-37846

---

**CELLECT BIOTECHNOLOGY LTD.**

(Translation of registrant's name into English)

---

**23 Hata'as Street  
Kfar Saba, Israel 44425**  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):

This Form 6-K is incorporated by reference into the registrant's Registration Statements on Form S-8 (Registration No. 333-214817, 333-220015 and 333-225003) and on Form F-3 (Registration No. 333-219614 and 333-212432).

---

---

On July 5, 2018, Celect Biotechnology Ltd. (the "Company") reconvened its annual general meeting of shareholders at which the Company's ordinary shareholders and ADS holders passed all agenda items as originally proposed, as described further in Exhibit 99.1 to the Company's Form 6-K furnished by the Company to the Securities and Exchange Commission on May 24, 2018.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Collect Biotechnology Ltd.

Date: July 6, 2018

By: /s/ Eyal Leibovitz  
Name: Eyal Leibovitz  
Title: Chief Financial Officer